Skip to main content
REGENXBIO Inc. logo

REGENXBIO Inc. — Investor Relations & Filings

Ticker · RGNX ISIN · US75901B1070 LEI · 549300EOES47LATSET33 US Manufacturing
Filings indexed 744 across all filing types
Latest filing 2026-05-14 Interim / Quarterly Rep…
Country US United States of America
Listing US RGNX

About REGENXBIO Inc.

https://regenxbio.com/

REGENXBIO Inc. is a clinical-stage company focused on the development and commercialization of gene therapies. The company's mission is to improve lives by delivering one-time treatments for a broad range of common and rare diseases. Central to its approach is the proprietary NAV® Technology Platform, an extensive portfolio of adeno-associated virus (AAV) vectors designed for targeted gene delivery. REGENXBIO's therapeutic pipeline includes product candidates for diseases in the retinal, metabolic, and neurodegenerative areas. The company operates with integrated, in-house manufacturing capabilities to support its clinical programs from development through to potential commercialization.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report
2026-05-14 English
8-K
Regulatory Filings
2026-05-14 English
DEF 14A - REGENXBIO Inc. (0001590877) (Filer)
Proxy Solicitation & Information Statement
2026-04-14 English
8-K - REGENXBIO Inc. (0001590877) (Filer)
Regulatory Filings
2026-03-20 English
8-K - REGENXBIO INC. (0001590877) (Filer)
Regulatory Filings
2026-02-10 English
4 Filing
Director's Dealing
2026-02-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.